Sarcoma: Cardiovascular and Oncologic Considerations

Sarcomas are a heterogeneous group of connective tissue tumors that can occur at any anatomical site. This includes the heart and great vessels, where angiosarcoma, leiomyosarcoma, intimal sarcoma, and undifferentiated sarcomas are the dominant histologic subtypes. These presentations are as complex as treatment planning, which often requires a multimodality approach. For these tumors, as well as sarcomas in other sites, multiple treatments carry risks of cardiotoxicity. Crucially, treatment universally includes high cumulative doses of anthracyclines, requiring risk modification using dexrazoxane, infusional administration, or liposomal formulations. Furthermore, multiple other therapies for sarcoma are associated with cardiovascular side effects. This review highlights the unique aspects of care for cardiac sarcomas, cardiovascular considerations of systemic agents used to treat sarcoma, the pediatric sarcoma population, and how cardiac surveillance of sarcoma patients can be approached.

Authors

Institutions

Publication Details

Journal
JACC CardioOncology
Published
2025-11-20
DOI
https://doi.org/10.1016/j.jaccao.2025.09.005
Citations
1
Primary Topic
Cardiac tumors and thrombi
Type
article
Field-Weighted Citation Impact
1.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Sarcoma: Cardiovascular and Oncologic Considerations

Daniel S. Lefler, Anju Nohria, Mark Agulnik, Jacquelyn Crane et al.
1 citations
JACC CardioOncology
Cardiac tumors and thrombi
1.39
article

Sarcoma: Cardiovascular and Oncologic Considerations

Daniel S. Lefler, Anju Nohria, Mark Agulnik, Jacquelyn Crane, Michael G. Fradley, Elise F. Nassif
article en
1 citations

Abstract

Sarcomas are a heterogeneous group of connective tissue tumors that can occur at any anatomical site. This includes the heart and great vessels, where angiosarcoma, leiomyosarcoma, intimal sarcoma, and undifferentiated sarcomas are the dominant histologic subtypes. These presentations are as complex as treatment planning, which often requires a multimodality approach. For these tumors, as well as sarcomas in other sites, multiple treatments carry risks of cardiotoxicity. Crucially, treatment universally includes high cumulative doses of anthracyclines, requiring risk modification using dexrazoxane, infusional administration, or liposomal formulations. Furthermore, multiple other therapies for sarcoma are associated with cardiovascular side effects. This review highlights the unique aspects of care for cardiac sarcomas, cardiovascular considerations of systemic agents used to treat sarcoma, the pediatric sarcoma population, and how cardiac surveillance of sarcoma patients can be approached.

JACC CardioOncologyVol. 7(7)
University of Southern California (US), Brigham and Women's Hospital (US), Children's Hospital of Philadelphia (US), The University of Texas MD Anderson Cancer Center (US), University of Pennsylvania (US)
Openalex Percentile: Top 13%
Cardiac tumors and thrombi
1.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Sarcoma: Cardiovascular and Oncologic Considerations — Daniel S. Lefler, Anju Nohria, et al. · JACC CardioOncology (2025) | TGRS Research Map | TGRS